SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull is surging as investors react to two major catalysts: the termination of a dilutive equity facility and the SEC's approval to remove pattern day trading restrictions, which is expected to drive significant user activity. The community is buzzing over the stock's potential for a multi-month recovery, with many comparing its current valuation to larger competitors and expressing bullish sentiment as the stock breaks through key resistance levels.

Avis Budget Group, Inc. engages in the provision of vehicle sharing and rental services. It operates through the Americas and International segments. The Americas segment includes vehicle rental and car sharing operations in North America, South America, Central America, and the Caribbean. The International segment is involved in vehicle rental and car sharing operations in Europe, the Middle East, Africa, Asia, and Australasia. The company was founded in 1946 and is headquartered in Parsippany, NJ.

Avis Budget Group Inc

Avis Budget Group (CAR) is seeing extreme volatility as a textbook short squeeze continues, driven by an exceptionally low float with the majority of shares held by a few key institutional investors. The community is intensely focused on the mechanical nature of the rally and the potential for a massive, abrupt retracement, while debating whether the company will issue a share offering to capitalize on the inflated valuation.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group is trending as investors digest the company's strong first-quarter earnings and revenue beat, coupled with a raised full-year earnings outlook that signals a successful shift toward margin-focused growth. Community discussion remains heavily divided between long-term holders celebrating a potential multi-year turnaround and bears skeptical of ongoing regulatory investigations and customer attrition, while traders are actively monitoring the stock for a broader breakout toward higher resistance levels.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group Inc. is experiencing intense volatility driven by news of an increased stake from strategic partner Uber, which has fueled speculation regarding the companys future in the robotaxi space. While some investors view the recent capital raises and expansion efforts as a foundational step toward commercialization, the community remains deeply divided, with many expressing frustration over persistent share dilution and the stock's proximity to all-time lows.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is rallying on significant volume as investors interpret aggressive accumulation and the upcoming U.S. redomicile as catalysts that outweigh recent short-seller reports. The community is actively dismissing bearish narratives, focusing instead on the company's critical role in the optical interconnect space and its deep-tech partnerships with major semiconductor players.

Applied Digital Corporation

Applied Digital is trending as investors closely monitor an upcoming lease deadline, fueling community speculation about a major hyperscaler announcement that could serve as a catalyst for the stock. While some traders are expressing frustration over the recent consolidation, others are bullishly positioning themselves for a breakout, citing strong institutional accumulation and the firm's strategic role in AI infrastructure development.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending following the successful commercial launch of ANKTIVA in Saudi Arabia, which investors see as a significant validation of the company's global expansion strategy. The community is actively debating the stock's potential for a short squeeze amid high short interest, while simultaneously discussing the broader impact of international market access and ongoing regulatory pressure on the FDA.

Lightwave Logic, Inc. is a development stage company which engages in the commercialization of electro-optic photonic devices. The firm offers the P2ICTM technology platform which uses in-house proprietary organic polymers. Its products include electro-optical modulation devices and proprietary polymer photonic integrated circuits. The company was founded on June 24, 1997 and is headquartered in Englewood, CO.

Lightwave Logic Inc

Lightwave Logic is currently trending due to intense speculation surrounding its electro-optic polymer technology, which investors are positioning as a critical enabler for high-speed AI data centers. The community is actively debating the company's transition from research-stage development to foundry-integrated production, with significant interest focused on its technical partnerships, upcoming conference presentations, and potential for major industry adoption.

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble Inc. is trending as investors rally around the companys strategic shift into the AI cloud and GPU infrastructure space, fueled by a high-profile share exchange deal with Northern Data and significant support from Tether. The community is actively discussing a potential short squeeze, citing elevated short interest and the anticipation of new catalyst milestones, leading many to hold for long-term growth while monitoring key price levels.

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor Technologies is seeing intense community focus as traders debate the potential for a short squeeze amid high short interest and a technical reversal setup. Investors are actively discussing the company's turnaround strategy, specifically highlighting positive signals in home acquisition volume and institutional positioning as catalysts that could drive a re-rating.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Citizens reiterated $TSHA Market Outperform-$6 and said, We continue to highlight TSHA as an opportunity based on the efficacy in Rett, clean safety (non-systemic) and regulatory clarity. 
$NGNE $ACAD $ALPMY 
Citizens JMP added: 
A key consideration for investors interested in TSHA has been comparison to NGNE, the most relevant Rett 
gene therapy competitor. 
 
We continue to see distinct differences between the Rett clinical strategies of TSHA and NGNE and supportive data: 
Overall, both TSHA &amp; NGNE maintain that their asset has better biodistribution with their chosen administration route— intrathecal lumbar (IT-L) for TSHA and intracerebrovascular (ICV) for NGNE. 
 
Based on the more involved procedure required for 
ICV administration, we think TSHA has a slight edge on route of administration. In terms of comparison on biodistribution, we think that the clinical data can speak for itself here; both assets appear to deliver gene therapy to the critical brain structures imparting a clinical effect.

Bruce Wilson

BofA⬆️ $TSHA&#39;s PT to $9 from $8 and reiterated at a Buy. 
BofA currently assigns TSHA-102 a 60% LoS &amp; 40% mkt shr for peak risk-adj&#39;d sales of $1.3B in &#39;31 (&#39;27 launch), 
whereas its KOLs think the geneTx could capture 80% of mkt. 
$ACAD $NGNE 
Here&#39;s what BofA had to say:

StockTwits Web

Taysha Gene Therapies Inc

Acadia Pharmaceuticals Inc

Neurogene Inc

Quantumup

Raymond James🏁 $TSHA Strong Buy/$13 
$NGNE $ACAD $ALPMY  
Raymond James said: 
Initiating coverage of Taysha Gene Therapies (TSHA) with a Strong Buy rating and $13 price target, as we think TSHA is well-positioned for success in its pivotal trial for patients with Rett syndrome (RTT), based on strong results from Part A of the Phase 1/2 REVEAL trial and constructive feedback from FDA. 
 
Raymond James added:

ASTELLAS PHARMA/ADR

 Market Outperform-$6 and said, We continue to highlight TSHA as an opportunity based on the efficacy in Rett, clean safety (non-systemic) and regulatory clarity. 


 
Citizens JMP added: 
A key consideration for investors interested in TSHA has been comparison to NGNE, the most relevant Rett 
gene therapy competitor. 
 
We continue to see distinct differences between the Rett clinical strategies of TSHA and NGNE and supportive data: 
Overall, both TSHA & NGNE maintain that their asset has better biodistribution with their chosen administration route— intrathecal lumbar (IT-L) for TSHA and intracerebrovascular (ICV) for NGNE. 
 
Based on the more involved procedure required for 
ICV administration, we think TSHA has a slight edge on route of administration. In terms of comparison on biodistribution, we think that the clinical data can speak for itself here; both assets appear to deliver gene therapy to the critical brain structures imparting a clinical effect.